CoChat

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Insulin Degludec: Pharmacokinetics in Patients with Renal Impairment

Open access

Abstract

BACKGROUND: Insulin degludec is a new-generation basal insulin with an ultra-long duration of action. We evaluated the pharmacokinetic properties of insulin degludec in subjects with normal renal function; mild, moderate or severe renal impairment; or end-stage renal disease (ESRD) undergoing hemodialysis. METHODS: Thirty subjects (n = 6 per group) received a single subcutaneous dose of 0.4 U/kg insulin degludec. Blood samples up to 120 h post-dose and fractionated urine samples were collected. RESULTS: The ultra-long pharmacokinetic properties of insulin degludec were preserved in subjects with renal impairment, with no statistically significant differences in absorption or clearance, compared with subjects with normal renal function. In subjects with ESRD, pharmacokinetic parameters were similar whether the insulin degludec pharmacokinetic assessment period included hemodialysis or not, and total exposure was comparable to subjects with normal renal function. Simulated mean steady-state pharmacokinetic profiles were comparable between groups. CONCLUSION: This study indicated dose adjustments due to impaired renal function should not be required for insulin degludec.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s40262-013-0113-2

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Trial design for non-ESRD subjects with various degrees of renal impairment, and ESRD subjects. ESRD end-stage renal disease
Fig. 1 Trial design for non-ESRD subjects with various degrees of renal impairment, and ESRD subjects. ESRD end-stage renal diseaseCC BY-NC · PubMed Central
Fig. 2 Total exposure of insulin degludec vs. creatinine clearance following a single dose of insulin degludec (0.4 U/kg subcutaneously). AUC 0–120h area under the insulin degludec serum concentration–time curve from 0 to 120 h
Fig. 2 Total exposure of insulin degludec vs. creatinine clearance following a single dose of insulin degludec (0.4 U/kg subcutaneously). AUC 0–120h area under the insulin degludec serum concentration–time curve from 0 to 120 hCC BY-NC · PubMed Central
Fig. 3 Simulated mean insulin degludec (IDeg) concentrations at steady state (IDeg 0.4 U/kg subcutaneously)
Fig. 3 Simulated mean insulin degludec (IDeg) concentrations at steady state (IDeg 0.4 U/kg subcutaneously)CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

3 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 27 references

Research works printed but not linked: 3

  1. Lynes W, Tyler JF, Lawrence A. Renal impairment does not affect insulin aspart pharmacokinetics in type 1 diabetes. Diabetes. 2001;50(suppl 2):A441–2.
  2. Jacobsen LV, Popescu G, Plum A. Pharmacokinetics of insulin detemir in subjects with renal or hepatic impairment. Diabetologia. 2002;45(suppl 1):A259.
  3. Kurtzhals P, Heise T, Strauss HM, et al. Multi-hexamer formation is the underlying basis for the ultra-long glucose-lowering effect of insulin degludec. Diabetologia. 2011;54(Suppl 1):S426.

Cited by

See all 76

Metadata

Authors
Kiss, I., Arold, G., Roepstorff, C., Bøttcher, S. G., Klim, S., & Haahr, H.
Affiliations
  • Szent Imre Egyetemi Oktatókórház (HU)
  • PRA Health Sciences (US)
  • Novo Nordisk (Denmark) (DK)
Corresponding author
Kiss, István
Venue
Clinical Pharmacokinetics
Published
2013-10-26
Volume
53
Issue
2
Pages
175-183
ISSN
  • 0312-5963 (ISSN-L)
  • 1179-1926
OpenAlex
W2037694686
Cited by
75
References
27
Citations by year
2025: 2 · 2024: 3 · 2023: 5 · 2022: 6 · 2021: 1 · 2020: 9 · 2019: 4 · 2018: 7 · 2017: 5 · 2016: 16 · 2015: 12 · 2014: 4 · 2013: 1
FWCI
8.65
Type
journal article
Language
en
Open access
Locations
  • Clinical Pharmacokinetics (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
  • Amgen
  • Sanofi
  • Novo Nordisk
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
Keywords
insulin degludec, pharmacokinetics, renal dysfunction, end-stage renal disease, hemodialysis, basal insulin, ultra-long-acting insulin, dose adjustment, drug clearance, urinary excretion
MeSH terms
Aged, Diabetes Mellitus, Type 2, Female, Renal Dialysis, Humans, Hypoglycemic Agents, Kidney, Male, Middle Aged, Dialysis Solutions, Insulin, Long-Acting, Renal Insufficiency

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Insulin Degludec: Pharmacokinetics in Patients with Renal Impairment. https://app.cochat.ai/papers/10.1007/s40262-013-0113-2
The paper
Kiss, I., Arold, G., Roepstorff, C., Bøttcher, S. G., Klim, S., & Haahr, H. (2014). Insulin Degludec: Pharmacokinetics in Patients with Renal Impairment. Clinical Pharmacokinetics. https://doi.org/10.1007/s40262-013-0113-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.